Key facts

Invented name
  • Vimizim
  • Vimizim (elosulfase alfa)
Active substance
Recombinant human N-acetylgalactosamine-6-sulfatase (BMN110)
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
PIP number
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of mucopolysaccharidosis, type IVA (Morquio-A syndrome)
Route(s) of administration
Intravenous use
Contact for public enquiries
BioMarin Europe Limited
United Kingdom
E-mail: biomarin-europe@bmrn.com 
Tel. +44 (0)20 7420 0800
Fax +44 (0)20 7420 0829
Decision type
PM: decision on the application for modification of an agreed PIP


Related content

How useful was this page?

Add your rating